8-K - REGENXBIO Inc. | StockGist

Current Report Details

Event Type

Regulation Fd

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

of this Current Report on Form 8‑K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193

Regulation Fd

8.01

. Other Events. On February 7, 2026, the Company received a CRL from the FDA regarding the Company’s BLA for RGX-121, the Company's investigational gene therapy

Other Event

9.01

. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated February 9, 2026. 104 The cover page from this Current Report

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1